PT TIMAH Tbk Pays Rp1 Trillion in Taxes and Non-Tax Revenue to SupportNationalDevelopment... state contributions through tax payments and Non-Tax State Revenue (PNBP) amounting to Rp1.053 trillion.
611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy ... To assess the impact of BRAF mutation status and prior BRAFi/MEKi therapy on the efficacy of RP1 plus nivolumab from a post hoc subgroup analysis of the IGNYTE trial.
600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma ... RP1* ... RP1** + Nivo† ... RP1 ... RP1 readministration could occur as monotherapy if nivo was stopped due to nivo-related toxicity ... additional RP1 doses.
Maybank Indonesia 9M FY25 PBT rises 53.9% to Rp1.30 trillion. 9M FY25 Preview (Y-o-Y) PBT up 53.9% to Rp1.30 trillion while PATAMI rose 77.3% to Rp989 billion GrossOperating Income rose 2.9% to Rp6.95 trillion, backed by.
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026. Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 ... .
Replimune Announces FDAAcceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma ... "We are pleased the agency has accepted the resubmission of our BLA for RP1," said Sushil Patel, Ph.D., CEO of Replimune ... About RP1.
Jakarta (ANTARA) - Indonesia has successfully recovered Rp1.7 trillion (US$102.5 million) in embezzled state funds from corruption suspects during the first year of PresidentPrabowo Subianto’s administration ...Related news ... Related news ... Editor.
Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC) ... To report the efficacy and safety of RP1 plus nivolumab in the NMSC cohort from the IGNYTE trial ... RP1 1 × 106 ... RP1 + weeks.